SEARCH

SEARCH BY CITATION

Cited in:

CrossRef

This article has been cited by:

  1. 1
    Pavan Kumar Mankal, Jean Abed, Jose David Aristy, Khushboo Munot, Upma Suneja, Ellen S. Engelson, Donald P. Kotler, Relative effects of heavy alcohol use and Hepatitis C in decompensated chronic liver disease in a hospital inpatient population, The American Journal of Drug and Alcohol Abuse, 2015, 41, 2, 177

    CrossRef

  2. You have free access to this content2
    K. Bichoupan, J. M. Schwartz, V. Martel-Laferriere, E. R. Giannattasio, K. Marfo, J. A. Odin, L. U. Liu, T. D. Schiano, P. Perumalswami, M. Bansal, P. J. Gaglio, H. Kalia, D. T. Dieterich, A. D. Branch, J. F. Reinus, Effect of fibrosis on adverse events in patients with hepatitis C treated with telaprevir, Alimentary Pharmacology & Therapeutics, 2014, 39, 2
  3. 3
    Gloria Searson, Ellen S. Engelson, Damaris Carriero, Donald P. Kotler, Treatment of chronic hepatitis C virus infection in the United States: some remaining obstacles, Liver International, 2014, 34, 5
  4. 4
    Patricia A. Cioe, Michael D. Stein, Kittichai Promrat, Peter D. Friedmann, A Comparison of Modified Directly Observed Therapy to Standard Care for Chronic Hepatitis C, Journal of Community Health, 2013, 38, 4, 679

    CrossRef

  5. 5
    A. C. Moorman, S. C. Gordon, L. B. Rupp, P. R. Spradling, E. H. Teshale, M. Lu, D. R. Nerenz, C. C. Nakasato, J. A. Boscarino, E. M. Henkle, N. J. Oja-Tebbe, J. Xing, J. W. Ward, S. D. Holmberg, Baseline Characteristics and Mortality Among People in Care for Chronic Viral Hepatitis: The Chronic Hepatitis Cohort Study, Clinical Infectious Diseases, 2013, 56, 1, 40

    CrossRef

  6. 6
    Adeyemi O Adedeji, Stefan G Sarafianos, Future treatment strategies for novel Middle East respiratory syndrome coronavirus infection, Future Medicinal Chemistry, 2013, 5, 18, 2119

    CrossRef

  7. 7
    Nae-Yun Heo, Young-Suk Lim, Han Chu Lee, Yung Sang Lee, Kang Mo Kim, Kwan Soo Byun, Kwang-Hyub Han, Kwan Sik Lee, Seung Woon Paik, Seung Kew Yoon, Dong Jin Suh, High effectiveness of peginterferon alfa-2a plus ribavirin therapy in Korean patients with chronic hepatitis C in clinical practice, Clinical and Molecular Hepatology, 2013, 19, 1, 60

    CrossRef

  8. 8
    Julia Uhanova, Robert B Tate, Douglas J Tataryn, Gerald Y Minuk, A population-based study of the epidemiology of hepatitis C in a North American population, Journal of Hepatology, 2012, 57, 4, 736

    CrossRef

  9. 9
    John P. Rice, David Burnett, Helena Tsotsis, Mary J. Lindstrom, Daniel D. Cornett, Patricia Voermans, Jill Sawyer, Rob Striker, Michael R. Lucey, Comparison of hepatitis C virus treatment between incarcerated and community patients, Hepatology, 2012, 56, 4
  10. 10
    Melissa R. Stein, Irene J. Soloway, Karen S. Jefferson, Robert J. Roose, Julia H. Arnsten, Alain H. Litwin, Concurrent group treatment for hepatitis C: Implementation and outcomes in a methadone maintenance treatment program, Journal of Substance Abuse Treatment, 2012, 43, 4, 424

    CrossRef

  11. 11
    Jennifer R. Kramer, Fasiha Kanwal, Peter Richardson, Minghua Mei, Hashem B. El-Serag, Gaps in the achievement of effectiveness of HCV treatment in national VA practice, Journal of Hepatology, 2012, 56, 2, 320

    CrossRef

  12. 12
    Stuart C. Gordon, Paul J. Pockros, Norah A. Terrault, Robert S. Hoop, Ami Buikema, David Nerenz, Fayez M. Hamzeh, Impact of disease severity on healthcare costs in patients with chronic hepatitis C (CHC) virus infection, Hepatology, 2012, 56, 5
  13. 13
    Alexander Y. Walley, Jeanette M. Tetrault, Peter D. Friedmann, Integration of substance use treatment and medical care: A special issue of JSAT, Journal of Substance Abuse Treatment, 2012, 43, 4, 377

    CrossRef

  14. 14
    Paul J. Gaglio, Noah Moss, Camille McGaw, John Reinus, Direct-Acting Antiviral Therapy for Hepatitis C: Attitudes Regarding Future Use, Digestive Diseases and Sciences, 2011, 56, 5, 1509

    CrossRef

  15. 15
    Jorge-Shmuel Delgado, Yael Baumfeld, Victor Novack, Shulamit Monitin, Alan Jotkowitz, Ohad Etzion, Alexander Fich, Efficacy of combined pegylated interferon and ribavirin therapy in Jewish patients of Israel suffering from chronic hepatitis C, Hepatology International, 2011, 5, 4, 985

    CrossRef

  16. 16
    J. Grebely, J. Bryant, P. Hull, M. Hopwood, Y. Lavis, G. J. Dore, C. Treloar, Factors associated with specialist assessment and treatment for hepatitis C virus infection in New South Wales, Australia, Journal of Viral Hepatitis, 2011, 18, 4
  17. 17
    Joseph Torresi, Doug Johnson, Heiner Wedemeyer, Progress in the development of preventive and therapeutic vaccines for hepatitis C virus, Journal of Hepatology, 2011, 54, 6, 1273

    CrossRef

  18. 18
    Zvi Ackerman, Orit Pappo, Iddo Z. Ben-Dov, The prognostic value of changes in serum ferritin levels during therapy for hepatitis C virus infection, Journal of Medical Virology, 2011, 83, 7
  19. 19
    Rachel A. Lindor, Keith D. Lindor, The value of observational research in liver diseases, Hepatology, 2011, 53, 1